Germline mutations in cancer predisposition genes are frequent in sporadic sarcomas

Associations of sarcoma with inherited cancer syndromes implicate genetic predisposition in sarcoma development. However, due to the apparently sporadic nature of sarcomas, little attention has been paid to the role genetic susceptibility in sporadic sarcoma. To address this, we performed targeted-g...

Full description

Saved in:
Bibliographic Details
Main Authors: Chan, Sock Hoai, Lim, Weng Khong, Nur Diana Binte Ishak, Li, Shao-Tzu, Goh, Wei Lin, Tan, Gek San, Lim, Kiat Hon, Teo, Melissa, Ng, Cedric Chuan Young, Malik, Simeen, Tan, Mann Hong, Teh, Jonathan Yi Hui, Chin, Francis Kuok Choon, Kesavan, Sittampalam, Selvarajan, Sathiyamoorthy, Tan, Patrick, Teh, Bin Tean, Soo, Khee Chee, Mohamad Farid, Quek, Richard, Ngeow, Joanne
Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
Format: Article
Language:English
Published: 2018
Subjects:
Online Access:https://hdl.handle.net/10356/87842
http://hdl.handle.net/10220/46812
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
Description
Summary:Associations of sarcoma with inherited cancer syndromes implicate genetic predisposition in sarcoma development. However, due to the apparently sporadic nature of sarcomas, little attention has been paid to the role genetic susceptibility in sporadic sarcoma. To address this, we performed targeted-genomic sequencing to investigate the prevalence of germline mutations in known cancer-associated genes within an Asian cohort of sporadic sarcoma patients younger than 50 years old. We observed 13.6% (n = 9) amongst 66 patients harbour at least one predicted pathogenic germline mutation in 10 cancer-associated genes including ATM, BRCA2, ERCC4, FANCC, FANCE, FANCI, MSH6, POLE, SDHA and TP53. The most frequently affected genes are involved in the DNA damage repair pathway, with a germline mutation prevalence of 10.6%. Our findings suggests that genetic predisposition plays a larger role than expected in our Asian cohort of sporadic sarcoma, therefore clinicians should be aware of the possibility that young sarcoma patients may be carriers of inherited mutations in cancer genes and should be considered for genetic testing, regardless of family history. The prevalence of germline mutations in DNA damage repair genes imply that therapeutic strategies exploiting the vulnerabilities resulting from impaired DNA repair may be promising areas for translational research.